Exploration of backbone space in foldamers containing α- and β-amino acid residues:: Developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-xL

被引:67
作者
Sadowsky, Jack D.
Murray, Justin K.
Tomita, York
Gellman, Samuel H.
机构
[1] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA
[2] Georgetown Univ, Ctr Med, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA
关键词
foldamers; helical structures; parallel synthesis; peptidomimetics; protein-protein interactions;
D O I
10.1002/cbic.200600546
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein-protein interactions play crucial roles in cell-signaling events and are often implicated in human disease. Molecules that bind tightly to functional protein-surface sites and show hgih stability to degradative enzymes could be valuable pharmacological tools for dissection of cell-signaling networks and might ultimately lead to thereapeutic agents. We recently described oligomers containing both alpha- and beta-amino acid residues that bind tightly to the BH3 recognition site of the anti-apoptotic protein Bcl-x(L). The oligomers with the highest affinity had a nine-residue N-terminal segment with a 1:1 alpha:beta residue repeat and a six-residue C-terminal segment containing exclusively proteinogenic alpha-residues. The N-terminal portions of such (alpha/beta + alpha)-peptides are highly resistant to proteolysis, but the C-terminal alpha-segments are susceptible. This study emerged from efforts to modify the alpha-segment in an (alpha/beta + alpha)-peptide in a way that would diminish proteolytic degradation but retain high affinity for Bcl-x(L). Some of the oligomers reported here could prove useful in certain biological applications, particularly those for which extended incubation in a biological milieu is required.
引用
收藏
页码:903 / 916
页数:14
相关论文
共 84 条
  • [1] Exploiting natural peptide diversity:: novel research tools and drug leads
    Adermann, K
    John, H
    Ständker, L
    Forssmann, WG
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2004, 15 (06) : 599 - 606
  • [2] Converting a peptide into a drug: Strategies to improve stability and bioavailability
    Adessi, C
    Soto, C
    [J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) : 963 - 978
  • [3] Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
    Arkin, MR
    Wells, JA
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) : 301 - 317
  • [4] Molecular recognition of protein-ligand complexes: Applications to drug design
    Babine, RE
    Bender, SL
    [J]. CHEMICAL REVIEWS, 1997, 97 (05) : 1359 - 1472
  • [5] Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs
    Baell, JB
    Huang, DCS
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) : 851 - 863
  • [6] Modulation of protein-protein interactions with small organic molecules
    Berg, T
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (22) : 2462 - 2481
  • [7] Berg T., 2003, ANGEW CHEM, V115, P2566
  • [8] Anatomy of hot spots in protein interfaces
    Bogan, AA
    Thorn, KS
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1998, 280 (01) : 1 - 9
  • [9] Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
    Certo, Michael
    Moore, Victoria Del Gaizo
    Nishino, Mari
    Wei, Guo
    Korsmeyer, Stanley
    Armstrong, Scott A.
    Letai, Anthony
    [J]. CANCER CELL, 2006, 9 (05) : 351 - 365
  • [10] Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
    Chen, L
    Willis, SN
    Wei, A
    Smith, BJ
    Fletcher, JI
    Hinds, MG
    Colman, PM
    Day, CL
    Adams, JM
    Huang, DCS
    [J]. MOLECULAR CELL, 2005, 17 (03) : 393 - 403